The ad networks say no.
Your growth doesn’t have to
You can't just buy your way to the top
Rescheduling changed a lot. It didn't change advertising.
- On 23 April 2026, FDA-approved marijuana products and products under a qualifying state medical marijuana licence were placed in Schedule III.
- A broader rescheduling process opened, with an expedited hearing running from 29 June 2026.
- Schedule III status has real implications for research and for tax treatment under 280E.
- Recreational and adult-use cannabis remains Schedule I, as does anything outside an FDA-approved product or a state medical licence.
- Google, Meta and the major platforms still restrict cannabis advertising. Their policies are commercial decisions, written for a national audience, and they don't move automatically with federal scheduling.
- State advertising rules are unchanged — age gating, audience thresholds, proximity restrictions and claim limits all still apply exactly as before.
Two things that end businesses, not campaigns
Health claims. Saying a product treats, cures, prevents or diagnoses anything makes it an unapproved drug in the FDA's view — the agency has issued warning letters to cannabis and CBD companies for precisely that, and it's also among the fastest routes to a licence problem. Educational content, never outcome claims.
Your email platform. Several mainstream providers prohibit cannabis in their acceptable use policies and will terminate an account, occasionally taking the list with it. We build on cannabis-friendly platforms from day one, so you're not rebuilding an audience you already earned.
Sources: DEA marijuana rescheduling actions · DOJ announcement, April 2026. Federal and state cannabis law is moving quickly — treat this as a summary current at time of writing, and verify anything material with your counsel. We don't provide legal advice.
Your competitors can't buy their way past you either
The channels that actually grow cannabis brands